Factor XI inhibition in cardiovascular disease

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Hematology

Background:

• Cardiovascular disease is a leading cause of death globally, necessitating effective antithrombotic therapies.
• Current anticoagulants carry bleeding risks, limiting their use in high-risk patients.
• Factor XI (FXI) inhibitors represent a novel class of anticoagulants aiming to balance efficacy with reduced bleeding.

Purpose of the Study:

• To review the development and potential of Factor XI (FXI) inhibitors as next-generation anticoagulants.
• To discuss the mechanistic rationale, therapeutic potential, and ongoing clinical evaluation of FXI inhibitors.
• To highlight the advantages of FXI inhibitors over existing therapies like direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs).

Main Methods:

• Review of mechanistic considerations, epidemiological data, and animal studies supporting FXI's role in thrombosis.
• Analysis of different classes of FXI inhibitors (antisense oligonucleotides, monoclonal antibodies, small molecules).
• Examination of Phase II trial results and ongoing Phase III trials (e.g., OCEANIC-STROKE, LIBREXIA).

Main Results:

• Phase II trials suggest FXI inhibitors may offer similar or reduced bleeding rates compared to existing agents.
• Early trial terminations highlight challenges in patient selection and optimal dosing.
• Ongoing Phase III trials are crucial for establishing efficacy in stroke, atrial fibrillation, and acute coronary syndrome.

Conclusions:

• FXI inhibitors show significant promise as safer and potentially more effective anticoagulants.
• Further research and Phase III trials are essential to define their clinical utility and optimal use.
• FXI inhibitors may address limitations of current antithrombotic strategies, particularly regarding bleeding risk.